SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX) has scheduled a conference call and live webcast on August 15, 2022, at 8:30 a.m. EDT to discuss its financial results for Q2 ended June 30, 2022. The company, focusing on innovative antifungal medicines, recently introduced BREXAFEMME, FDA-approved on June 1, 2021, for treating difficult-to-treat infections. The call will provide a corporate update, enhancing transparency for investors. Details for joining the call are provided, with a replay available for 90 days on the company’s website.

Positive

• SCYNEXIS announced a conference call to discuss Q2 financial results, fostering transparency with investors.
• FDA approval of BREXAFEMME on June 1, 2021, strengthens the company's product portfolio.

Negative

• None.

JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Monday, August 15, 2022 to provide a corporate update and discuss the Company’s financial results for the second quarter ended June 30, 2022.

Conference call and webcast details:

Investors (domestic): (877) 704-4453
Investors (international): (201) 389-0920
Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1555622&tp_key=54aa49f539
Conference ID: 13730704

A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp, as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS launched its first commercial product in the U.S., BREXAFEMME^® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, clinical investigation and development of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Debbie Etchison
Debbie.etchison@scynexis.com

FAQ

What is the date of SCYNEXIS's next conference call?

SCYNEXIS's next conference call is scheduled for August 15, 2022.

What financial results will SCYNEXIS discuss on the conference call?

SCYNEXIS will discuss its financial results for the second quarter ended June 30, 2022.

Where can I find the replay of the SCYNEXIS conference call?

The replay of the SCYNEXIS conference call will be available on the company’s website for 90 days after the event.

What is BREXAFEMME and when was it approved?

BREXAFEMME is an antifungal medication approved by the FDA on June 1, 2021.

What are the key areas of focus for SCYNEXIS?

SCYNEXIS focuses on developing medicines for difficult-to-treat and drug-resistant infections.